ReviewMycopathologia2007
Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis.
Review in Mycopathologia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 74 citations in OpenAlex.
- Trial
- Article
- Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.The Journal of antimicrobial chemotherapy · 2024Article
- Serum Galactomannan: A Predictor of Poor Outcomes in Peritoneal Dialysis Patients With Fungal Peritonitis.Kidney international reports · 2024Article
- Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients.Acta haematologica · 2023Article
- [The clinical value of diagnostic-driven therapy of invasive fungal disease (IFD) type unclassified CⅡgroup in multiple myeloma patients during inducing chemotherapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Has Aspergillus PCR Come to the Age of Maturity?Mycopathologia · 2016Article
- A case of invasive pulmonary aspergillosis with direct invasion of the mediastinum and the left atrium in an immunocompetent patient.Tuberculosis and respiratory diseases · 2014Article
- Characteristics of invasive aspergillosis in neutropenic haematology patients (Sousse, Tunisia).Mycopathologia · 2014Article
- PCR as a screening test for invasive aspergillosis in haematological patients: a pilot study.Mycopathologia · 2014Article
- Reproducibility of positive results for the detection of serum galactomannan by Platelia™ aspergillus EIA.Mycopathologia · 2013Article
- Multiple bilateral pulmonary "fungus balls" in an immunocompetent patient unsuitable for surgical treatment: efficacy of azoles treatment.Mycopathologia · 2013Article
- Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?The Journal of infection · 2012Article
- Article
- PCR-based diagnosis of human fungal infections.Expert review of anti-infective therapy · 2009Review
- Central nervous system Aspergillus infection after epidural analgesia: diagnosis, therapeutic challenges, and literature review.Diagnostic microbiology and infectious disease · 2009Article
- Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2009Article
- Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay.Clinical and vaccine immunology : CVI · 2009Article
- Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus.Eukaryotic cell · 2008Article
- Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid.BMC infectious diseases · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of invasive fungal infections (IFI) remains a challenge, particularly for diseases caused by filamentous fungi such as Aspergillus species. Unfortunately, many patients affected by these conditions are not identified before autopsy. Therefore, there is a need for new diagnostic methods for IFI. Galactomannan is a soluble antigen released during hyphal growth in tissues. A commercially available sandwich ELISA assay that detects galactomannan has been used in Europe for many years and is now approved for use in the USA. The test has an excellent negative predictive value in the detection of invasive aspergillosis (IA) in high-risk patients. In addition, it is more sensitive than culture and allows IA to be diagnosed before clinical manifestations occur. However, false-negative and false-positive results in certain populations are the main limitations to its use. The purpose of this review is to summarize the current knowledge about galactomannan testing in patients at risk for IA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.